UCB's Global Corporate Website

This section is intended for media and financial analysts

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 




The figures of the guidance 2024 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2023.


2024 Revenue

€ 5.5 - 5.7 billion

taking into account the launches and the continued solid contributions from the existing product portfolio.

2024 adj. EBITDA 

23.0% - 24.5%

reflecting investments in launches around the globe to offer potential new solutions for people living with severe diseases and the commitment to invest into research and development to advance the late-stage and early development pipeline.

2024 Core EPS

€ 3.70 - 4.40

based on an average of 190 million shares outstanding


2025 Revenue

at least € 6 billion

2025 adj. EBITDA

Low- to mid-thirties

(at the lower end of the range)

2025 Improved ESG

rating performance


Contact UCB IR Team

investor-relations@ucb.com or a specific team member: